In respect to their cardiovascular effects among patients with T2DM, both GLP-1RAs and SGLT2is have been shown to reduce the risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), with GLP-1RAs reducing the risk of non-fatal stroke to a greater extent [3, 6]
Tsuboi Y, Fujino Y, Kobayashi K, Saheki T, Yamada T (2001) High serum pancreatic secretory trypsin inhibitor before onset of type II citrullinemia
Feeling queasy? Metavo Nausea Spray delivers fast-acting, gentle relief for upset stomach and nauseanaturally
Many people dont get enough vitamin B12
Expanding Indications: Approval for obesity, and potential approval for cardiovascular risk reduction in patients with diabetes or obesity, will significantly broaden its patient base
It was the epitome of the grey area between legal and illegal doping